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Abstract
Purpose. Patients with soft tissue sarcoma (STS) who have previously received standard chemotherapy including
adriamycin (doxorubicin), ifosfamide, cyclophosphamide and DTIC (dacarbazine) have very limited therapeutic options.
It is important to identify new drugs with some activity in this disease and we therefore undertook this trial to determine
the antitumor activity of paclitaxel (Taxol).
Methods. We conducted a phase II study of paclitaxel in patients with STS who had received prior standard
chemotherapy. Paclitaxel was administered at a starting dose of 200 mg m
2 2 as a 24-h infusion with STS premedication,
every 21 days or upon hematologic recovery (absolute granulocyte count (AGC) $ 1500/m l, platelets$ 100 000/m l).
Neupogen was not used routinely. The study was conducted based on a two-stage design proposed by Simon. Responses
were assessed radiographically using standard criteria.
Results. Nineteen eligible patients were treated in the ® rst stage of the study. The median age was 50 years (range 20± 68
years), and there were nine females and 10 males with Zubrod performance status of 1 or 2. One patient achieved a minor
response. Median AGC nadir was 0.1/m l on day 12 with absolute neutropenia lasting 5 days. Median platelet nadir was
171 000/m l on day 9. There were no grade 3/4 non-hematologic toxicities and no deaths related to treatment.
Discussion. Paclitaxel, at this dose and schedule, is well tolerated but inactive in this patient population.
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Introduction
Paclitaxel (Taxol; Bristol-Meyers Squibb Co.,
Princeton, NJ, USA) is a novel antimicrotubule
agent with a unique mechanism of action. It has
been studied in a wide variety of malignancies with
varying levels of ef® cacy.
1 Given its `broad spec-
trum’ activity, we performed a phase II study of
paclitaxel in patients with soft tissue sarcoma (STS)
who had received prior standard chemotherapy.
Since leiomyosarcomas of gastrointestinal (GI) ori-
gin do not respond well to standard chemotherapy
including adriamycin and ifosfamide, patients with
this histology were eligible without prior exposure to
chemotherapy. The major objectives of the study
were to evaluate the ef® cacy and the toxicity pro® le
of paclitaxel in patients with STS.
Subjects and methods
Eligibility
Patients older than 16 years of age with histologic
proof of a STS were eligible. All patients had
received prior standard chemotherapy including
adriamycin, ifosfamide, cyclophosphamide and
DTIC (dacarbazine) with the exception of patients
with GI leiomyosarcoma who could be chemo-
therapy naõÈ ve. Patients were required to have a
Zubrod performance status of 0± 2, a life expectancy
of at least 12 weeks, measurable or evaluable dis-
ease, and relatively normal organ function de® ned
as absolute granulocyte count (AGC) of $ 1500/m l,
platelet count of $ 100 000/m l, total bilirubin
, 1.5 mg dl
2 1 serum creatinine , 1.6 mg dl
2 1 and
cardiac ejection fraction of . 50% without evidence
of congestive heart failure. No other concurrent
therapy was allowed and all patients signed an in-
formed consent. Exclusion criteria included preg-
nancy, serious non-malignant intercurrent illnesses,
serious conduction abnormalities or cardiac arrhyth-
mias requiring anti-arrhythmic medications.
Treatment plan
To minimize the risk of anaphylactoid reactions, all
patients were premedicated with 20 mg of dexam-
ethasone given orally, 12 and 6 h prior to paclitaxel,
and 50 mg of diphenhydramine and 300 mg of
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Table 1. Dose modi® cation scheme
Criteria for hematologic toxicity Criteria for non-hematologic toxicity
Dose levels Granulocyte
(mg m
2 2) nadir/m l Platelet nadir/m l Modi® cation Grade Dose modi® cation
2 2 150 . 2000 . 100 000 Increase 2 levels 0± 1 Increase 1 level
2 1 175 1000± 2000 75 000± 100 000 Increase 1 level 2 No change
0 200 , 500* , 50 000** Decrease 1 level 3 Decrease 1 level
1 1 225 4 Decrease 2 levels or stop
1 2 250
*Signi® cant morbidity: organ infection, sepsis syndrome, failure to recover to $ 1500/m l by day 28.
**Signi® cant morbidity: bleeding, platelet transfusions for $ 7 days, failure to recover to $ 100 000/m l by day 28.
cimetidine were given intravenously 1 h prior to
paclitaxel. The starting dose of paclitaxel was
200 mg m
2 2 administered as a 24-h continuous
intravenous infusion via a central venous catheter.
Cycles were repeated every 21 days or upon com-
plete recovery. Granulocyte colony-stimulating fac-
tor was not used prohylactically, but was allowed for
therapeutic indications. Dose modi® cation was per-
formed based on hematologic and non-hematologic
toxicities as outlined in Table 1.
Pretreatment evaluation and follow-up studies
Prior to enrolment on the protocol, all patients
underwent a complete history and physical examin-
ation. Laboratory studies included a complete blood
count (CBC) with differential and platelets, chem-
istry pro® le (SMA 12), electrolytes and magnesium,
repeated prior to each cycle. Appropriate radio-
graphic studies were performed to de® ne the extent
of tumor. A cardiac scan or 2D echocardiogram was
performed to document the cardiac ejection fraction
prior to initiation of treatment. Following paclitaxel,
patients were followed with at least once weekly
CBC with differential and platelet counts. Cross-
sectional radiographic imaging to assess response
was performed every two cycles.
Response criteria
Complete response (CR) was de® ned as the disap-
pearance of all clinical evidence of tumor. Partial
response (PR) was de® ned as a $ 50% reduction in
the sum of the products of the biperpendicular
diameters of measurable lesions without the appear-
ance of new lesions for at least 3 weeks. Minor
response (MR) was de® ned as a decrease in tumor
size between 25 and 49%. Stable disease (SD) was
de® ned as a , 25% change in the dimensions of the
tumor and progressive disease (PD) was de® ned as
a # 25% increase in the sum of the perpendicular
diameters and/or appearance of new lesions. Tu-
mors that could not be bidimensionally measured
were deemed evaluable. In these instance, re-
gression, progression or no change were de® ned as
unequivocal decrease, increase or no change in the
tumor size and volume as agreed upon by two
independent investigators. Development of new dis-
ease was also considered progression of disease.
Statistical considerations
The trial was conducted in two stages, using the
optimal two-stage design proposed by Simon.
2
Based on the hypothesis that a response rate of
< 5% would be of no interest and a response rate of
$ 20% would be signi® cant, 15 patients were re-
quired and 19 patients were entered in the ® rst stage
of the study. If no responses were seen in these
patients, the study would have to be terminated,
otherwise a total of 35 patients needed to be ac-
crued. This design afforded a power of 92% to
detect a response rate of at least 20% with a rejec-
tion error of 10%.
Results
Patient characteristics
Nineteen patients were entered on the study (Table
2). The median age was 50 years (range 20± 68
years). There were nine females and 10 males with
a Zubrod performance status of 1 or 2. Eight pa-
tients had leiomyosarcoma, three had unclassi® ed
sarcoma, three had stromal sarcoma of the breast,
two had pleomorphic rhabdomyosarcoma, and one
each had alveolar soft-part sarcoma, malignant
® brous histiocytoma and synovial sarcoma. Seven-
teen patients had metastatic disease and two had
persistent or locally recurrent disease. Median
number of cycles of paclitaxel chemotherapy
administered was two (range 1± 7).
Response
No objective CR or PR was seen. One patient with
metastatic lung disease from a high-grade stromal
sarcoma of the breast had an MR. Seven other
patients had SD while 11 patients had PD.Taxol in soft tissue sarcomas 97
Table 2. Patient characteristics
Characteristic Number
Patients entered 19
Age, years
Median 50
Range 20± 68
Zubrod performance status
1 18
2 1
Sex
Male 10
Female 9
Race
Oriental 2
Other 1
White 16
Histology
Leiomyosarcoma 8
Gastrointestinal 6
Uterus/retroperitoneal 2
Unclassi® ed 3
Stromal sarcoma of breast 3
Others 5
Disease status
Metastases 17
Uncontrolled primary
or local recurrence 2
Prior therapy
Surgery 14
Radiation 3
Chemotherapy 12
Discussion
According to the American Cancer Society’s esti-
mates, approximately 6400 new STS were diag-
nosed in 1996.
3 Chemotherapeutic agents with
signi® cant activity in these tumors include adri-
amycin, ifosfamide, cyclophosphamide and DTIC.
Patients whose disease recurs or progresses after a
trial of these standard agents have a guarded prog-
nosis, and trials of new and interesting drugs are
warranted. We have previously published our results
with paclitaxel in bone sarcomas.
4 In this similar
trial, we chose to evaluate the activity of pactitaxel at
a dose of 200 mg m
2 2 administered as a 24-h
infusion, every 3 weeks in patients failing prior
treatment with standard chemotherapy. No objec-
tive responses were noted in our trial suggesting a
low level of activity of this drug in this patient
population. A recently reported trial of paclitaxel in
patients with previously untreated advanced STS
revealed a response rate of 12.5%.
5 The patient
population selected for our trial was refractory to
standard chemotherapy, and therefore less likely to
respond to paclitaxel. Six patients had leiomyo-
sarcoma of GI origin which did not respond to
paclitaxel.
In conclusion, paclitaxel at a dose of 200 mg m
2 2
over 24-h every 3 weeks in patients with STS refrac-
tory to standard chemotherapy is well tolerated but
inactive. Phase II trials of new agents are warranted.
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Toxicity
Forty-one courses were administered at dose level 0
and two courses each were administered at dose
levels 1 and 2 1. The National Cancer Institute’s
common toxicity criteria were used to assess tox-
icities. The median AGC nadir was 100/m l on day
12 of the cycle, lasting a median of 7 days (range
2± 12) and the median platelet count nadir was
171 000/m l on day 9 of the cycle. Only ® ve cycles
were complicated by febrile neutropenia. There
were no grade 3± 4 non-hematologic toxicities and
no deaths related to treatment.